Programs that reduce the spread of HIV should be praised and promoted, not criticized and condemned, said the Canadian HIV/AIDS Legal Network in response to a report being released by the International Narcotics Control Board (INCB).
A Johns Hopkins study has proven false established medical practice that an antiretroviral drug widely used to treat hepatitis B liver infections was safe to use on its own in patients co-infected with HIV.
HIV prevention research was responsible for the recent revelation that male circumcision can play an important role in protecting men from infection with the deadly virus.
Adcock Ingram, South Africa?s largest pharmaceutical company, is set to start manufacturing antiretrovirals (ARVs) with immediate effect, following approval by the Medicines Control Council (MCC).
A total of 373 new HIV cases were reported to the Department of Health, Hong Kong, last year, the highest annual number ever recorded. The figure represents a 19% increase on the 313 cases in the preceding year.
Gilead Sciences, Inc. (Nasdaq:GILD) announced the completion of a Phase II clinical trial of GS 9137, a novel oral HIV integrase inhibitor. The clinical study met its primary endpoint of non-inferiority in viral load reduction in HIV-positive patients receiving 50 mg or 125 mg of GS 9137 once daily, each boosted with 100 mg of ritonavir, in combination with an optimized background antiretroviral regimen compared to a boosted comparator protease inhibitor regimen (p=0.02 for the 125 mg arm).
Healthcare professionals are advised that when considering therapy with Baraclude in an HIV/HBV co-infected patient not receiving HAART, the risk of developing HIV resistance cannot be excluded based on current information.
The government of The Gambia gave the most senior United Nations official in the country 48 hours to leave the country starting Friday, following remarks she made criticising Gambian President Yahya Jammeh?s widely-publicised cure for HIV/AIDS.
Gilead Sciences, Inc. (Nasdaq:GILD) announced the completion of a Phase II clinical trial of GS 9137, a novel oral HIV integrase inhibitor.
The National Family Health Survey (NFHS), the most extensive study on health and nutrition in India, said in its latest report only 57 percent of women have heard of AIDS.